Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Georgopoulos, A.
Right arrow Articles by Graninger, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Georgopoulos, A.
Right arrow Articles by Graninger, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 497-501
© 1999 The British Society for Antimicrobial Chemotherapy

Efficacy of ß-lactam and inhibitor combinations in a diffusion chamber model in rabbits

A. Georgopoulos*, A. Buxbaum and W. Graninger

University Clinic for Internal Medicine I, Clinical Department for Infectious Diseases and Chemotherapy, University of Vienna, Austria

Using a diffusion chamber in rabbits, we evaluated therapy with the combination of ceftriaxone plus the ß-lactamase inhibitor tazobactam in comparison with ceftriaxone alone. One sensitive and one resistant strain of Escherichia coli, Enterobacter cloacae and Klebsiella pneumoniae were inoculated into one of the six diffusion chambers, implanted in the same animal. In order to simulate pharmacokinetics in humans, both substances were administered in decreasing doses. Ceftriaxone was given 0, 2, 4 and 6 h after infection in dosages of 45, 35, 25 and 15 mg/kg of body weight, while tazobactam was administered either in one dose at 0 h, or divided into two doses at 0 and 1 h or 0 and 4 h, or divided into three doses at 0, 1 and 4 h after infection. The ratio of ceftriaxone:tazobactam was fixed at 8:1. Ceftriaxone, in combination with tazobactam, given in one dose immediately after infection showed a significant reduction in bacterial count. All other combinations of ceftriaxone and tazobactam did not differ from ceftriaxone in monotherapy. Co-administration of the ß-lactamase inhibitor tazobactam significantly enhanced the activity of ceftriaxone against all three tested species.

* Correspondence address. University Clinic for Internal Medicine I, Clinical Department for Infectious Diseases and Chemotherapy, General Hospital of Vienna, Währinger Gürtel 18-20, A-1090 Vienna. Tel: +43-1-40400/5139; Fax: +43-1-40400/5167


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
P. G. Sohnle and B. L. Hahn
Effect of Prolonged Fluconazole Treatment on Candida albicans in Diffusion Chambers Implanted into Mice
Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3175 - 3179.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.